LGND
LIGAND PHARMACEUTICALS INC
Latest Form 4:Sale$2.1MbyHaas Jason (Director) · filed Aug 14, 2026
LIGAND PHARMACEUTICALS INC (LGND) has 51 SEC Form 4 filings (202 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Aug 14, 2026.
The most active filer is Director KOZARICH JOHN W with 11 filings. Insiders have net sold $28.5M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Todd C. Davis
- Employees:68
- HQ:Jupiter, CA, US
- IPO:1992-11-18
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$33.3M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
Market Cap
$5.6B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 7,138 | $2.1M | Aug 14 | SEC ↗ | |
Espinoza OctavioFirst in 5 months | Chief Financial Officer | Sale | 31,641 | $9.2M | Aug 14 | SEC ↗ |
| CLO & Secretary | Sale | 5,000 | $1.4M | Aug 4 | SEC ↗ | |
| CLO & Secretary | Sale | 5,000 | $1.6M | Jul 6 | SEC ↗ | |
| Director | Sale | 2,145 | $545K | Jun 18 | SEC ↗ | |
| Director | Sale | 6,461 | $1.7M | Jun 15 | SEC ↗ | |
| Director | Sale | 4,591 | $1.2M | Jun 12 | SEC ↗ | |
| Director | Sale | 500 | $125K | Jun 12 | SEC ↗ | |
| Director | Sale | 4,500 | $1.1M | Jun 12 | SEC ↗ | |
| CLO & Secretary | Sale | 5,000 | $1.1M | Jun 2 | SEC ↗ | |
| Director | Sale | 467 | $108K | May 15 | SEC ↗ | |
| Director | Sale | 459 | $103K | May 15 | SEC ↗ | |
| Director | Sale | 1,575 | $352K | May 15 | SEC ↗ | |
| CLO & Secretary | Sale | 5,000 | $1.2M | May 5 | SEC ↗ | |
| CLO & Secretary | Sale | 5,000 | $1.0M | Apr 2 | SEC ↗ | |
| Director | Sale | 467 | $94K | Apr 2 | SEC ↗ | |
LAMATTINA JOHN LFirst in 5 months | Director | Sale | 2,161 | $434K | Mar 31 | SEC ↗ |
| Director | Sale | 1,000 | $208K | Mar 25 | SEC ↗ | |
| Chief Financial Officer | Sale | 3,057 | $688K | Mar 13 | SEC ↗ | |
Reardon AndrewFirst filing | CLO & Secretary | Sale | 5,000 | $1.0M | Mar 6 | SEC ↗ |
| Chief Financial Officer | Sale | 13,423 | $2.8M | Mar 6 | SEC ↗ | |
Sabba Stephen LFirst filing | Director | Sale | 2,034 | $410K | Mar 5 | SEC ↗ |
| Director | Sale | 467 | $94K | Mar 4 | SEC ↗ | |
| Director | Sale | 467 | $91K | Feb 4 | SEC ↗ | |
| Director | Sale | 467 | $89K | Jan 6 | SEC ↗ | |
Espinoza OctavioFirst filing | Chief Financial Officer | Sale | 1,804 | $340K | Dec 16 | SEC ↗ |
| Director | Sale | 467 | $91K | Dec 3 | SEC ↗ | |
LAMATTINA JOHN LFirst filing | Director | Sale | 4,179 | $859K | Nov 12 | SEC ↗ |
Gray Nancy RyanFirst filing | Director | Sale | 6,571 | $1.4M | Nov 12 | SEC ↗ |
| Director | Sale | 467 | $89K | Nov 5 | SEC ↗ | |
| Director | Sale | 467 | $84K | Oct 3 | SEC ↗ | |
| Director | Sale | 10,000 | $1.7M | Sep 24 | SEC ↗ | |
KOZARICH JOHN WFirst filing | Director | Sale | 467 | $76K | Sep 4 | SEC ↗ |
Congress trading LGND
See timeline →- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-29
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
LIGAND PHARMACEUTICALS INC is in the Healthcare sector.